KEAP1 and Hepatic steatosis: Overall, the current study reports enhanced Nrf2 activity, genetically via Keap1-KD, prevented fasting-induced fatty liver by inhibiting fatty acid transport and impairing activation of the Pparα signaling pathway in liver.